Literature DB >> 3732370

Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing.

S W Sanders, N Haering, H Mosberg, H Jaeger.   

Abstract

Twenty-four healthy volunteers participated in a study on the disposition of ergotamine following oral and rectal administration. Plasma samples were collected surrounding each dose of medication and a new mass spectrometry method was used for quantitation of the samples. A mean peak plasma concentration of 454 pg/ml was measured an average of 50 min following a 2 mg rectal dose. In contrast, the 2 mg oral dose produced a mean peak plasma concentration of 21 pg/ml an average of 69 min following the dose. Area under the concentration time curve indicated a relative bioavailability of 5% for the oral dosage form. Conflicting data on ergotamine disposition highlight the factors which may be responsible for determining bioavailability and pharmacologic activities of the compound.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732370     DOI: 10.1007/bf00541538

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Measurement of ergotamine in human plasma by triple sector quadrupole mass spectrometry with negative ion chemical ionization.

Authors:  N Haering; J A Settlage; S W Sanders; R Schuberth
Journal:  Biomed Mass Spectrom       Date:  1985-05

2.  Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; N T Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

3.  Exercise-induced increments in plasma levels of propranolol and noradrenaline.

Authors:  G A Hurwitz; J G Webb; T Walle; S A Bai; H B Daniell; L Gourley; C Boyd Loadholt; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

4.  Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Circadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis.

Authors:  K Semenowicz-Siuda; A Markiewicz; J Korczyńska-Wardecka
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-12

6.  Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay.

Authors:  T T Kleimola
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

7.  Specific radioimmunoassay of ergot peptide alkaloids in plasma.

Authors:  H F Schran; H J Schwarz; K C Talbot; L J Loeffler
Journal:  Clin Chem       Date:  1979-11       Impact factor: 8.327

8.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

9.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

Review 10.  Influence of food intake on presystemic clearance of drugs.

Authors:  A Melander; A McLean
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

View more
  8 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 2.  Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.

Authors:  Jonathan Jia Yuan Ong; Milena De Felice
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 3.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 4.  The clinician's approach to the management of headache.

Authors:  M Maizels
Journal:  West J Med       Date:  1998-03

5.  Prolonged absorption and susceptibility to enterohepatic circulation after oral administration of ergot alkaloids in ewes.

Authors:  Ahmed Almousa; Rossalin Yonpiam; Barry Blakley; Ahmad N Al-Dissi
Journal:  Can J Vet Res       Date:  2022-04       Impact factor: 0.897

6.  The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.

Authors:  A M Brown; T L Patch; A J Kaumann
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

Review 7.  Headache.

Authors:  N H Raskin
Journal:  West J Med       Date:  1994-09

8.  Dynamic in vitro intestinal barrier model coupled to chip-based liquid chromatography mass spectrometry for oral bioavailability studies.

Authors:  Milou J C Santbergen; Meike van der Zande; Arjen Gerssen; Hans Bouwmeester; Michel W F Nielen
Journal:  Anal Bioanal Chem       Date:  2019-12-21       Impact factor: 4.142

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.